Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 10/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.36 |
| ▸ | SYK | P43405 | 3/20 | 0.34 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9949639 | 1.00 | KDM4E (0.41) | KDM4EALDH1A1SMN1; SMN2CCNT1CNR2 | |
| SCHEMBL9949642 | 0.84 | SMN1; SMN2 (0.45) | KDM4EALDH1A1SMN1; SMN2CCNT1 | |
| SCHEMBL9950123 | 0.84 | SMN1; SMN2 (0.45) | KDM4EALDH1A1SMN1; SMN2CCNT1 | |
| SCHEMBL9950504 | 0.81 | CCNT1 (0.48) | ALDH1A1CCNT1BRAF | |
| SCHEMBL9950176 | 0.81 | PIM1 (0.43) | CCNT1BRAF | |
| SCHEMBL9949605 | 0.80 | CCNT1 (0.57) | CCNT1 | |
| SCHEMBL9950495 | 0.78 | CCNT1 (0.49) | KDM4EALDH1A1CCNT1BRAF | |
| SCHEMBL9949992 | 0.78 | CCNT1 (0.50) | CCNT1BRAF | |
| SCHEMBL9950800 | 0.77 | SIRT6 (0.44) | CNR2SIRT6 | |
| SCHEMBL9949449 | 0.77 | CCNT1 (0.51) | CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK4, CDK1, CCNI | KDM4E 1223/4885ALDH1A1 1528/4885SMN1; SMN2 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.